Literature DB >> 9637784

PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection.

T Hirsch1, D Decaudin, S A Susin, P Marchetti, N Larochette, M Resche-Rigon, G Kroemer.   

Abstract

One critical step of the apoptotic process is the opening of the mitochondrial permeability transition (PT) pore leading to the disruption of mitochondrial membrane integrity and to the dissipation of the inner transmembrane proton gradient (Delta Psim). The mitochondrial PT pore is a polyprotein structure which is inhibited by the apoptosis-inhibitory oncoprotein Bcl-2 and which is closely associated with the mitochondrial benzodiazepine receptor (mBzR). Here we show that PK11195, a prototypic ligand of the 18-kDa mBzR, facilitates the induction of Delta Psim disruption and subsequent apoptosis by a number of different agents,including agonists of the glucocorticoid receptor,chemotherapeutic agents (etoposide, doxorubicin),gamma irradiation, and the proapoptotic second messenger ceramide. Whereas PK11195 itself has no cytotoxic effect, it enhances apoptosis induction by these agents. This effect is not observed for benzodiazepine diazepam, whose binding site in the mBzR differs from PK11195. PK11195 partially reverses Bcl-2 mediated inhibition of apoptosis in two different cell lines. Thus, transfection-enforced Bcl-2 overexpression confers protection against glucocorticoids and chemotherapeutic agents, and this protection is largely reversed by the addition of PK11195. This effect is observed at the level of Delta Psim dissipation as well as at the level of nuclear apoptosis. To gain insights into the site of action of PK11195, we performed experiments on isolated organelles. PK11195 reverses the Bcl-2-mediated mitochondrial retention of apoptogenic factors which cause isolated nuclei to undergo apoptosis in a cell-free system. Mitochondria from control cells, but not mitochondria from Bcl-2-overexpressing cells, readily release such apoptogenic factors in response to atractyloside, a ligand of the adenine nucleotide translocator. However, control and Bcl-2-overexpressing mitochondria respond equally well to a combination of atractyloside and PK11195. Altogether, these findings indicate that PK11195 abolishes apoptosis inhibition by Bcl-2 via a direct effect on mitochondria. Moreover, they suggest a novel strategy for enhancing the susceptibility of cells to apoptosis induction and, concomitantly, for reversing Bcl-2-mediated cytoprotection. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637784     DOI: 10.1006/excr.1998.4084

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  46 in total

1.  Suppression of E1A-mediated transformation by the p50E4F transcription factor.

Authors:  E R Fernandes; R J Rooney
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

2.  Regulation of the inner membrane mitochondrial permeability transition by the outer membrane translocator protein (peripheral benzodiazepine receptor).

Authors:  Justina Sileikyte; Valeria Petronilli; Alessandra Zulian; Federica Dabbeni-Sala; Giuseppe Tognon; Peter Nikolov; Paolo Bernardi; Fernanda Ricchelli
Journal:  J Biol Chem       Date:  2010-11-09       Impact factor: 5.157

3.  Functional characterization of the human translocator protein (18kDa) gene promoter in human breast cancer cell lines.

Authors:  Amani Batarseh; Keith D Barlow; Daniel B Martinez-Arguelles; Vassilios Papadopoulos
Journal:  Biochim Biophys Acta       Date:  2011-09-18

Review 4.  Mitochondria: pharmacological manipulation of cell death.

Authors:  Lisa Bouchier-Hayes; Lydia Lartigue; Donald D Newmeyer
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 5.  Mitochondria: a target for cancer therapy.

Authors:  Jeffrey S Armstrong
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

6.  Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.

Authors:  Joel G R Weaver; Agathe Tarze; Tia C Moffat; Morgane Lebras; Aurelien Deniaud; Catherine Brenner; Gary D Bren; Mario Y Morin; Barbara N Phenix; Li Dong; Susan X Jiang; Valerie L Sim; Bogdan Zurakowski; Jessica Lallier; Heather Hardin; Peter Wettstein; Rolf P G van Heeswijk; Andre Douen; Romano T Kroemer; Sheng T Hou; Steffany A L Bennett; David H Lynch; Guido Kroemer; Andrew D Badley
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

Review 7.  Mitochondrial medicine: pharmacological targeting of mitochondria in disease.

Authors:  J S Armstrong
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

8.  The mitochondrial translocator protein, TSPO, inhibits HIV-1 envelope glycoprotein biosynthesis via the endoplasmic reticulum-associated protein degradation pathway.

Authors:  Tao Zhou; Ying Dang; Yong-Hui Zheng
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

Review 9.  Inhibition of mitochondrial membrane permeability as a putative pharmacological target for cardioprotection.

Authors:  D Morin; R Assaly; S Paradis; A Berdeaux
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

10.  Translocator protein blockade reduces prostate tumor growth.

Authors:  Arlee Fafalios; Ardavan Akhavan; Anil V Parwani; Robert R Bies; Kevin J McHugh; Beth R Pflug
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.